Several issues about autologous and allogeneic stem cell transplantations (auto and alloSCT) for CLL are unsettled including timing of transplant, role of pretreatment, remission status required for transplant, purging and conditioning regimen. In order to help to clarify these points, we analyzed 324 autoSCT and 135 alloSCT performed for B CLL and reported to EBMT registry between 1984 to 1999. Median age was 51 (29-61) and 45 (21-64) years and median time from diagnosis to SCT, and 41 (5-170) months for autoSCT and alloSCT respectively. Among autoSCT, 27% of the patients and 17% among alloSCT had received Fludarabine prior transplant. A complete remission (CR) at SCT was present in 36% of the patients in autoSCT group and 11% in alloSCT group, whereas 59% and 52% were in PR. As kind of transplant, 84% of patients received peripheral blood progenitor cells (PBPC) in autoSCT group and 60% of patients received bone marrow (BM) in alloSCT group. Purging of the graft was performed in 50% of autotransplanted patients and 30% of allotransplants were T-depleted. Forty-seven% of autotransplanted and 76% of allotransplanted patients received a TBI-containing conditioning. After alloSCT, 40% of patients developed an acute GVHD grades 2-4 and 40% a chronic GVHD. The projected 3-year survival after autoSCT was 80% ± 6% without a plateau and 54% ± 11% with a plateau after alloSCT (pϽ0.0001). Risk of relapse at 3 years postransplant was 40% ± 10% after autoSCT and 22 ± 12% after alloSCT. Using log rank comparisons, time from diagnosis Ͻ 3 years (p=0.005), CR at transplant (p=0.004), less than 2 lines of therapy pretransplant (p=0.03) and TBI (0.004) in autoSCT group and PBPC (p=0.08) and fludarabine prior transplant (p=0.04) in alloSCT group were identified as predictors for superior survival. Cox regression analysis considering age, sex, fludarabine, time from diagnosis, remission status and year of transplant confirmed transplantϽ 3 years and CR at SCT in autoSCT group (HR = 4 for autoSCT in PR and HR = 2.4 for autoSCT Ͼ 3 years) and Fludarabine (HR = 0.45) and PBPC in alloSCT group (HR = 0.7) as favorable prognostic factors for overall survival. In conclusion i) alloSCT for poor risk CLL patients give a possibility of cure with a significant favorable impact on outcome of prior Fludarabine and ii) early autoSCT and achievement of a status of minimal residual disease prior to transplant appear to be important prerequisites for a superior outcome after auto SCT for CLL. Prospective randomized studies are now needed to prove if these findings are of prognostic importance. Patients with Ph+ve CML who relapse after allogeneic stem cell transplant (SCT) may still achieve long term survival with donor lymphocyte transfusion (DLT). We aimed to assess retrospectively the prognostic effect of the DLT schedule (a single fixed dose vs escalating doses). On behalf of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation (EBMT) group, we investigated risk factors in 269 patients who were treated with DLT (186 with a single fixed dose, 83 with escalating doses) for either cytogenetic relapse (CYT, n=71), or hematologic relapse in chronic phase (HCP, n=150), or hematologic relapse in advanced phase (HAP, n=48) at 42 EBMT centers since 1988. Logistic regression analysis showed that complete cytogenetic response (CyCR) rate (overall=68%) was related with interval from SCT to relapse ((less than)6 months: RR=1; (greater than)6 months: RR=0.3, 95%CI=0.1-0.6), and disease stage at DLT (HAP: RR=1; CYT or HCP: RR=0.2, 95%CI=0.1-0.4), but not with DLT dose schedule or disease phase at SCT. At 5 years from DLT: survival was 67 (plusminus) 3 (% (plusminus) SE), DLT related mortality was 16 (plusminus) 3 (%(plusminus) SE), relapse incidence after a CyCR was 13 (plusminus) 3 (%(plusminus) SE). Cox regression gave the following results: disease phase at SCT (1stCP: RR=1; more advanced: RR=2.2, 95%CI=1.3-3.7), disease stage at DLT (CYT or HCP: 1; HAP: RR=3.4, 95%CI=2.0-5.7), and DLT dose schedule (fixed: RR=1; escalating: RR=0.2, 95%CI=0.1-0.4) were related with survival; DLT dose schedule (fixed: RR=1; escalating: RR=0.15, 95%CI=0.03-0.61) was related with DLT related mortality; disease phase at SCT (1stCP: RR=1; more advanced: RR=4.5, 95%CI=1.6-12.3), was related with relapse incidence after CyCR. Patient age and gender, donor gender, donor type (SIB vs MUD), recipient/donor sex combination, previous GvHD, and date of DLT were not significant. We conclude that, in patients with Ph+CML who relapse after allogeneic SCT, an escalating doses schedule was associated with a better survival and with a lower risk of DLT related mortality than a single fixed dose schedule. Positive selection of PBSC has been used in MM with the aim of reducing tumor cells contamination and thus improving outcome. However, a clinical benefit has not yet been demonstrated. 127 patients with newly diagnosed advanced MM were included into this phase III trial. Responders to 3 cycles of VAD were randomized to receive a CD34 selected graft (arm A, n=64) or an unselected graft (arm B, n= 63). PBPC were harvested following mobilization with cyclophosphamide 4g/m 2 and G-CSF S31
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(Filgastrim). The conditioning regimen in both arms was TBI and melphalan 140 mg/m 2 . CD34+ selection was performed in arm A using the CellPro Ceprate-SC device and resulted in a median purity of 88.5% and yield of 63%. Molecular analysis showed a median tumor cell depletion of 1.93 log (0.87-5.2). The median number of CD34+ cells reinfused was 7.3x106 CD34 cells/kg (1.4-50.4) in arm A and 15x106 CD34 cells/kg (1.8-99.2) in arm B. The median time to neutrophil engraftment (ANCϾ500) was 10 days in arm A (8-14) and 10 days in arm B (8-21). The median time to platelets engraftment (pltsϾ20x109/l) was 11 days in both arms but one patient in arm A never reached 20 x 109/l platelets without supportive transfusions. 13 episodes of serious infections between the time of neutrophil engraftment and day 100 were reported in arm A compared to only 1 in arm B. All the infections were viral except 1 bacterial and 1 protozoal. For 3 patients in arm A, these infections were fatal (parainfluenza, CMV and myocarditis of infective etiology). The overall transplant mortality was 2.7% (3 patients in arm A). There was no significant difference in CR rate as defined by EBMT/IBMTR/ABMTR criteria (22% in arm A and 13% in arm B) at 2 years follow-up. There is so far no significant difference in EFS and OS. Median follow-up is 23 months in arm B and 27 months in arm A. The median OS has not been reached yet and the projected probability of OS at 2 years is 73% in arm A and 84% in arm B. The projected 2 years relapse risk is 55% in arm A vs. 65% in arm B. In summary, CD34+ selection resulted in a 1.9 tumor cell depletion without delay in hematology recovery. However, current analysis shows no significant clinical benefit while the incidence of serious infections was significantly increased in the selected arm.
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Comparison of autologous and unrelated donor stem cell transplantation in MDS/sAM) R. Arnold, R. Brand, A. van Biezen, V. Rude, T. de Witte (Berlin, D) In patients with MDS/sAML transplant from a related donor is the first choice of therapy. If no related donor is available, there is the choice of autologous or unrelated transplantation. Between 1989 and 1999, 917 patients with MDS/sAML underwent autologous or matched unrelated donor transplantation and were registered in the data base of the CLWP of the EBMT; in 906 patients the donor type and stage was known. Primary unrelated donor transplantation without induction chemotherapy was performed in 138 patients (M-U). All other patients received induction chemotherapy and were transplanted in early stage of the disease (autologous mt, A-CR1 n=3D324, unrelated bmt, M-CR1 n=3D100) or advanced stage (A-no CR1 n=3D102, M-no CR1 n=3D242). We included all patients with age up to and including 56 years (90% of the patients) with known donor type and stage. This resulted in 813 patients available for the survival analysis. We have A-CR1=3D260, M-CR1=3D99, M-U=3D136, A-nCR1=3D78, M-no=3D240. The reason for restriction to the first 90% of the ages is to assure that we have overlapping age distributions to make valid comparisons between these subgroups after adjustment for age. The analyses hereafter restrict to 495 patients in the subgroups A-CR1, M-CR1 and M-U. Since only after 1989 M-CR1 patients present themselves, we have to restrict also by calendar year to avoid unacceptable correlation between calendar year and subgroup. Hence we are left with 468 patients among whome information on TBI was missing in 56 and on the interval between diagnosis and transplant in 9 cases. Survival, EFS and RI after transplant can not be analyzed properly by a (single) Cox model due to severe non-proportionality during the first 4 months after transplant. Interestingly the difference between the 3 subgroups after 4 months can adequately be described by a separate Cox analysis reflecting outcome in patients who actually survive the first 4 months after transplant. Hence we divided our analysis in 2 parts: [A] the first 4 months after transplant and [B] after 4 months for those surviving the first 4 months. TRM can be described by a single Cox model. For RI and TRM we analyze in the usual way over the entire period [C] . All analyses adjust for the (significant) covariates 'age of patient' and 'calendaryear' .[A] For survival and EFS the donor type is a highly significant factor, but only during the first 4 months. At 4 months, the average adjusted survival (resp EFS) after transplantation in M-U was 50% (45%); for M-CR1 72% (62%); and for A-CR1 93% (77%). The adjusted Hazard Ratios for M-U versus A-CR1 were 8.4 (survival) and 2.9 (EFS); for M-CR1 vs A-CR1 they were 4.0 and 1.8 resp.
[B] Having survived 4 months however, there is absolutely NO difference at all in survival during the remainder of time between the three subgroups! In EFS we do see some residual effect (due to long term effect of relapse incidence), although it does not reach statistical significance (3 year average survival varying between 40% and 60%). [C] For Relapse Incidence we see a very strong effect of calendar time(year of transplant) which is a strong effect modifier for the RI in thethree subgroups. For example, the RI after 36 months for transplants in 1990 was 80% for M-U, 64% for A-CR1 and 20% for M-CR1. The situation has changed completely by 1995 where the same outcome is now 30% for M-U, 62% for A-CR1and 28% for M-CR1. Finally for the analysis of TRM, we can use one model in which we adjust for calendar year and age of the patient in the usual way. The effect of donor type is again highly significant with a TRM (for a transplantaround 1995 and an average age of the patient) of 70% in M-U; 50% in M-CR1 and 10% in A-CR1. This difference may be due to a lower risk of infection. In conclusion: Again the proper choice of statistical models is essential to avoid biased estimates and facilitates clinical interpretation of the data. These data favour induction chemotherapy and transplantation in CR1. Patients untreated before transplant still have a considerable chance of surviving. TRM in unrelated transplantation and relapse in autologoustransplantation are high.
